MAPMI Ultra-Broad-Spectrum Pathogen mNGS Test CapitalBio

Name: MAPMI Ultra-Broad-Spectrum Pathogen mNGS Test
Brand: CapitalBiotech Co., Ltd.

Next-generation sequencing (NGS)- based metagenomic sequencing forms the basis of CapitalBiotech®MAPMI detection. This technology allows for the direct detection of nucleic acid in a sample, captures sequencing data for all present microorganisms, and supprts unbiased identification of potential pathogens.

Inquire Now

Features of MAPMI Extended-Spectrum Pathogenic Microorganism mNGS Detection

1. Detection of 16109 viruses, 13362 bacteria, 1659 fungi, 270 parasites, and 2500 drug resistance genes

2.

Targets	Sensitivity
virus	1000 copies/mL
Bacteria, fungi, and parasites	100 copies/mL

3. Target population

Patients who fall into this category have been identified as immunosuppressed hosts, patients with underlying disorders, and patients with severe infections who have been hospitalized multiple times.
Patients who repeatedly fail standard microbiological tests and have suboptimal treatment responses.
Patients who are clinically suspected of harboring emerging diseases and who show infectious signs.
Individuals who may be infected with specific virus.
Patients with additional clinical signs, prolonged fever, and/or infections of unknown etiology.
The MAPMI Test is also available at CapitalBiotech Medical Lab.